Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma
Nicholas Boddicker(Cornell University), James R. Cerhan(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Elliot Cahn(Mayo Clinic in Arizona), Yan W. Asmann(Mayo Clinic in Florida), Fadi Towfic, Thomas M. Habermann(Mayo Clinic in Arizona), Anne J. Novak(Mayo Clinic), Peter Martin(Northwestern University), Anita K. Gandhi(Bristol-Myers Squibb (United States)), Chuican Huang(Hainan Maternal and Child Health Hospital), Matthew J. Maurer(Mayo Clinic in Arizona), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Susan L. Slager(Mayo Clinic), Pinkal Desai(NewYork–Presbyterian Hospital), Brian K. Link(University of Iowa), Thomas E. Witzig(WinnMed), Andrew L. Feldman(Mayo Clinic in Arizona), Vivekananda Sarangi(Mayo Clinic)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k